A child who underwent allogeneic bone marrow transplantation for late relapsed <i>TCF3-ZNF384</i>-positive B-cell precursor acute lymphoblastic leukemia

DOI
  • Araki Mikie
    Department of Hematology and Oncology, Children’s Medical Center, Japanese Red Cross Aichi Medical Center Nagoya First Hospital
  • Yamashita Daiki
    Department of Hematology and Oncology, Children’s Medical Center, Japanese Red Cross Aichi Medical Center Nagoya First Hospital
  • Yoshida Nao
    Department of Hematology and Oncology, Children’s Medical Center, Japanese Red Cross Aichi Medical Center Nagoya First Hospital
  • Kitazawa Hironobu
    Department of Hematology and Oncology, Children’s Medical Center, Japanese Red Cross Aichi Medical Center Nagoya First Hospital
  • Akita Nobuhiro
    Department of Hematology and Oncology, Children’s Medical Center, Japanese Red Cross Aichi Medical Center Nagoya First Hospital
  • Miyajima Yuji
    Department of Pediatrics, Anjo Kosei Hospital
  • Hama Asahito
    Department of Hematology and Oncology, Children’s Medical Center, Japanese Red Cross Aichi Medical Center Nagoya First Hospital

Bibliographic Information

Other Title
  • <i>TCF3-ZNF384</i>陽性B前駆細胞性急性リンパ性白血病の晩期再発に対して同種骨髄移植を施行した一例

Search this article

Abstract

<p>We present the case of an 8-year-old girl diagnosed as having B-cell precursor acute lymphoblastic leukemia (BCP-ALL) at the age of 4 years. Her initial steroid response was good. The first remission was achieved after induction therapy and maintained with chemotherapy for 2.5 years. Bone marrow relapse occurred 4.5 years after the initial presentation and 2 years after therapy. A leukemia-related fusion gene test revealed TCF3-ZNF384 positivity. During second remission, bone marrow transplantation was performed from her HLA8/8 allele-matched father using a conditioning regimen (melphalan, 180 mg/m2; total-body irradiation, 12 Gy). Neutrophil recovery was achieved 17 days after transplantation, with no acute complications other than acute graft-versus-host disease of the skin. She remains disease-free one year after transplantation. The prognosis of recurrent TCF3-ZNF384-positive BCP-ALL is poor, and hematopoietic cell transplantation may provide good results. Although this patient achieved good results using a myeloablative conditioning regimen, the appropriate conditioning regimen intensity remains unclear, warranting future investigation.</p>

Journal

Keywords

Details 詳細情報について

Report a problem

Back to top